RxDoctor Payments DataLook up a doctor →

James Ellison, MD

Cardiovascular Disease · Chesterfield, MONPI 1992813745

Payments from drug & device makers

$266,705in general payments, 2019–2025

Across 650 payments — averaging $410.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$248K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Boehringer Ingelheim International GmbH$4K
  • Novartis$1K
  • Boston Scientific$896
  • Merck$834
  • plus $8K from 48 others
$1,483,245in research payments, 2019–2025

Across 3 payments — averaging $494,415 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$1.5M
  • Boehringer Ingelheim International GmbH$9K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim94$248,420
Takeda Pharmaceuticals U.S.A., Inc.8$4,032
Boehringer Ingelheim International GmbH1$3,696
Novartis82$1,192
Boston Scientific27$896
Merck38$834
Johnson & Johnson38$657
AstraZeneca34$656
Pfizer35$648
Amgen36$614
Bayer15$365
E.r. Squibb & Sons, L.L.C.19$343
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)21$333
Esperion Therapeutics, Inc.15$314
United Therapeutics Corporation18$310
Regeneron Healthcare Solutions, Inc.11$256
Medtronic(2 entities)2$248
Grifols USA, LLC14$238
Actelion Pharmaceuticals US, Inc.20$238
Cvrx, Inc.10$234
Sanofi-aventis U.S. LLC10$213
Impulse Dynamics (USA) Inc.9$212
Scpharmaceuticals Inc.9$199
Amarin Pharma, Inc.15$183
Kiniksa Pharmaceuticals International, PLC7$148
Heartflow, Inc.6$136
Medicure Pharma Inc.1$105
Sanofi4$78
Kowa Pharmaceuticals America, Inc.6$77
Siemens Medical Solutions USA, Inc.4$74
Mylan Specialty L.p.5$71
Baxter Healthcare2$53
Vital Connect, Inc2$46
Daiichi Sankyo Inc.2$46
Kestra Medical Technology Services, Inc.2$45
Gilead3$43
Electromed, Inc.3$43
Edwards Lifesciences2$41
Lexicon Pharmaceuticals, Inc.2$40
Philips North America LLC2$40
Novo Nordisk2$35
Abbott1$28
Kiniksa Pharmaceuticals, Ltd.1$28
Bardy Diagnostics, Inc.2$26
Lantheus Medical Imaging, Inc.1$25
Itamar Medical Inc1$23
Chiesi USA, Inc.1$21
Advanced Respiratory, Inc1$18
Sunovion Pharmaceuticals Inc.1$17
Sanofi Pasteur Inc.1$16
GSK1$15
Altathera Pharmaceuticals LLC1$14
Covis Pharma GmbH1$12
Cumberland Pharmaceuticals, Inc.1$12

How this compares

$266,705 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri →

Medicare billing

Part B allowed, 2024
$173,951
Medicare patients
2,702
Services billed
4,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Chesterfield

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →